When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab.

Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Dermatol Ther
Hlavní autoři: Damiani, Giovanni, Conic, Rosalynn RZ, de Vita, Valerio, Costanzo, Antonio, Regazzini, Roberto, Pigatto, Paolo DM, Bragazzi, Nicola L, Pacifico, Alessia, Malagoli, Piergiorgio
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445726/
https://ncbi.nlm.nih.gov/pubmed/30515970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.12793
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky